Overview

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks
Phase:
Phase 3
Details
Lead Sponsor:
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Collaborator:
Gilead Sciences
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination